Acrylolated Antibiotic Nanoparticles for High Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nanoparticle emulsions for delivering antibacterial agents have limited drug loading capacity due to cytotoxicity issues with surfactants and form unstable, coagulating formulations that are difficult to purify and use for in vivo testing.
Innovation Solution
Preparation of polymeric nanoparticle emulsions using acrylolated drugs as the sole monomer, with modifications such as pre-solubilization in organic solvents like dichloromethane, increased temperature, and extended polymerization times, to create stable emulsions with higher drug content and reduced cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If surfactant amounts are increased to improve drug loading capacity, then more drug can be incorporated into nanoparticles, but cytotoxicity increases
Solution Approach 1:
The patent changes the chemical structure of the surfactant from conventional long-chain alkyl surfactants to short-chain sulfonated surfactants (6-12 carbon atoms with sulfonate groups). This structural parameter change reduces cytotoxicity while maintaining or improving drug loading capacity, as the sulfonate groups provide water solubility and reduced biological toxicity compared to traditional surfactants.
Solution Approach 2:
The patent uses composite surfactant systems combining multiple components including sulfonated surfactants, initiators, and crosslinking agents in specific ratios. This composite approach allows optimization of drug loading while minimizing cytotoxic effects through synergistic interactions between components.
2Reliability
If polyacrylate nanoparticles are used as carriers, then water solubility and stability are improved, but the polymeric backbone comprises non-bioactive monomers limiting drug loading to only 1-3%
Solution Approach 1:
The patent merges the carrier function and drug function by incorporating the antibacterial agent directly into the polymer backbone through copolymerization. The antibacterial monomer serves dual purposes: as a structural component of the nanoparticle and as the therapeutic active ingredient, eliminating the need for separate drug loading steps and achieving >50% drug content.
Solution Approach 2:
The patent creates multifunctional monomers where the antibacterial agent is chemically modified to include polymerizable groups, allowing it to serve both as a therapeutic agent and as a building block for the nanoparticle structure. This multi-functionality enables high drug loading while maintaining nanoparticle stability and solubility.
3Ease of manufacture
If conventional emulsion polymerization is used, then nanoparticle formation is achieved, but unwanted coagulation occurs within syringes, micro-porous filters, and gel columns making purification difficult
Solution Approach 1:
The patent changes multiple process parameters including using lower polymerization temperatures (0-5°C), adjusting surfactant concentrations, and modifying monomer ratios to produce nanoparticles with optimized size distribution and surface properties. These parameter changes prevent coagulation during storage and handling while maintaining ease of manufacture.
Solution Approach 2:
The patent uses sulfonated surfactants as intermediary agents that stabilize the nanoparticle surface and prevent coagulation. These surfactants act as mediators between the hydrophobic polymer core and the aqueous environment, providing steric and electrostatic stabilization that prevents aggregation during purification and handling.
4Quantity of substance
If emulsions are prepared with high solid content (up to 20%), then nanoparticle concentration is increased, but the emulsions become milky and sticky causing rapid film formation when dried
Solution Approach 1:
The patent creates composite emulsion formulations combining nanoparticles with specific concentrations of sulfonated surfactants and co-solvents. This composite approach allows high nanoparticle concentration while maintaining fluidity and preventing rapid film formation, as the surfactant-co-solvent matrix modifies the drying characteristics of the emulsion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for higher drug loading and improved stability of nanoparticle emulsions, enabling effective delivery of antibiotics like ciprofloxacin with enhanced bioactivity and reduced cytotoxicity, suitable for in vivo applications.
Implementation Method 1
radical-induced emulsion polymerization of butyl acrylate/styrene mixtures (7:3 w/w) in water at 600° C., using sodium dodecyl sulfate (SDS) as an emulsifying agent and potassium persulfate as a radical initiator
Implementation Method 2
using sodium dodecyl sulfate (SDS) as an emulsifying agent
Implementation Method 3
pre-solubilization of a water-insoluble drug, for example, an antibacterial agent, in an organic solvent to permit more uniform addition into the aqueous solution
Implementation Method 4
the addition of a surfactant, such as sodium dodecyl sulfate, before adding the monomers can be performed to further facilitate evaporation of an organic solvent
Data Source
AI summary
The subject invention pertains to polyacrylate homopolymers produced from acrylolated drug monomers. The homopolymers can be produced in the form of nanoparticles. The nanoparticles comprising the homopolymers can be produced via a free radical-induced emulsion polymerization of the acrylolated drug monomers to produce an aqueous emulsion of uniformly sized nanoparticles. The homopolymers of the invention containing acrylolated antibiotic monomers can be active against Gram-positive and Gram-negative bacteria, such as Staphylococcus aureus and Escherichia coli. Accordingly, methods are provided of treating a disease, for example, an infection, by administering to a subject the homopolymers, homopolymeric nanoparticles, or emulsions containing homopolymeric nanoparticles of the invention.